Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Nov 14 - Nov 19
Commonly injected subcutaneously in small doses
7,9% 45%
RECENT GUIDANCE ON THE USE OF GLP-1 RAs IN PATIENTS WITH T2D In consideration of recently reported cardiovascular and renal outcome data, multiple organizations have published updated guidance over the last several years regarding the use of glucose-lowering agents in patients with T2D to mitigate cardiovascular and renal risks
The collective glucoregulatory actions of GLP1 make this peptide a potential powerful agent for the treatment of diabetes
The SURMOUNT-5 clinical trial published in The New England Journal of Medicine showed that Zepbound (tirzepatide) achieved an average weight loss of 20.2% compared to 13.7% with Wegovy (semaglutide) at 72 weeks
US$ 22.85
US$ 27.85
US$ 28.22
US$ 23.16
